Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

The route to a
new drug isn't
always clear...

NEXT

...but those familiar
with the terrain will
find a way...

NEXT

...to push through
on the journey
to success.

NEXT

01

02

03

Who We Are

Sygnature Discovery provides experienced, innovative, multi-disciplinary drug discovery teams to support client projects across a wide range of Therapeutic Areas and Target Classes.

ABOUT US

Therapeutic Areas

Oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.

DISCOVER

Diabetes

Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide.  We have established assays to support the investigation of diabetic therapies including functional assays to quantify insulin and Glucagon-Like Protein (GLP-1) secretion, as well as glucose transport. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.

DISCOVER

Neuroscience

Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.

DISCOVER

Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.

DISCOVER

Respiratory

We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects

DISCOVER

Immuno-oncology

Modulation of the immune system presents an exciting new approach for the therapeutic perturbation of cancer cell growth. Sygnature have developed a comprehensive platform to study the processes involved in immuno-oncology, including the assessment of cytokines, intracellular signalling, T-cell proliferation assays and antibody-dependent cell cytotoxicity (ADCC) assays.

DISCOVER

Anti-Infectives

Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.

DISCOVER

Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.

DISCOVER

Latest News

View All

Sygnature Discovery announces ambitious expansion plans with…

Sygnature Discovery proves commitment to cyber security

Sygnature Discovery appoints Dr Andy Black as…

Sygnature Discovery raises over £2,700 for Parkinson’s…

Upcoming Events

View All
2-6 Sep 2018

XXV EFMC International…

SLOVENIA

VISIT WEBSITE
30-01 Apr-May 2019

BioTrinity 2019

London, UK

VISIT WEBSITE
25-28 Sep 2018

Discovery on Target

Boston, USA

VISIT WEBSITE

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.